Last Updated : April 17, 2017
Details
FilesGeneric Name:
Carfilzomib
Project Status:
Complete
Therapeutic Area:
Multiple Myeloma (relapsed)
Manufacturer:
Amgen Canada Inc.
Brand Name:
Kyprolis
Project Line:
Reimbursement Review
Project Number:
PC0084-000
NOC Status at Filing:
Pre NOC
Performance Metric:
Achieved
Strength:
60 mg per vial
Tumour Type:
Myeloma
Indications:
Multiple Myeloma (relapsed)
Funding Request:
In combination with dexamethasone alone in the treatment of patients with relapsed multiple myeloma who have received 1 to 3 prior lines of therapy
Pre Noc Submission:
Yes
Sponsor:
Amgen Canada Inc.
Submission Date:
Submission Deemed Complete:
Prioritization Requested:
Not Requested
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Reimburse with clinical criteria and/or conditions
pERC Meeting:
Final Recommendation Issued:
Files
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.
Last Updated : April 17, 2017